These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35921431)

  • 1. New Cancer-Related Symptoms Predict Recurrence in CA19-9 Non-Expressers After Resection of Pancreatic Ductal Adenocarcinoma.
    Amburn T; Davenport D; Patel R; Moss J; Pandalai P; Kim J; Cavnar M
    Am Surg; 2023 Nov; 89(11):4469-4478. PubMed ID: 35921431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
    Rieser CJ; Zenati M; Hamad A; Al Abbas AI; Bahary N; Zureikat AH; Zeh HJ; Hogg ME
    Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative prediction of disease-free survival in pancreatic ductal adenocarcinoma patients after R0 resection using contrast-enhanced CT and CA19-9.
    Li D; Peng Q; Wang L; Cai W; Liang M; Liu S; Ma X; Zhao X
    Eur Radiol; 2024 Jan; 34(1):509-524. PubMed ID: 37507611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
    Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
    Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?
    Chen T; Zhang MG; Yu XJ; Liu L
    Asian Pac J Cancer Prev; 2015; 16(2):661-6. PubMed ID: 25684504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study.
    Imaoka H; Shimizu Y; Senda Y; Natsume S; Mizuno N; Hara K; Hijioka S; Hieda N; Tajika M; Tanaka T; Ishihara M; Niwa Y; Yamao K
    Pancreatology; 2016; 16(4):658-64. PubMed ID: 27178104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
    Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
    World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamics of Serum CA19-9 in Patients Undergoing Pancreatic Cancer Resection.
    van Oosten AF; Groot VP; Dorland G; Burkhart RA; Wolfgang CL; van Santvoort HC; He J; Molenaar IQ; Daamen LA
    Ann Surg; 2024 Mar; 279(3):493-500. PubMed ID: 37389896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of preoperative PNI and CA19-9 for pancreatic ductal adenocarcinoma: A multi-institutional retrospective study.
    Itoh S; Tsujita E; Fukuzawa K; Sugimachi K; Iguchi T; Ninomiya M; Maeda T; Kajiyama K; Adachi E; Uchiyama H; Utsunomiya T; Ikeda Y; Maekawa S; Toshima T; Harada N; Yoshizumi T; Mori M
    Pancreatology; 2021 Oct; 21(7):1356-1363. PubMed ID: 34426076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative maximum standardized uptake value and carbohydrate antigen 19-9 were independent predictors of pathological stages and overall survival in Chinese patients with pancreatic duct adenocarcinoma.
    Gu X; Zhou R; Li C; Liu R; Zhao Z; Gao Y; Xu Y
    BMC Cancer; 2019 May; 19(1):456. PubMed ID: 31092213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Biomarker-Based Scoring System Predicting Early Recurrence of Resectable Pancreatic Duct Adenocarcinoma.
    Ishido K; Kimura N; Wakiya T; Nagase H; Hara Y; Kanda T; Fujita H; Hakamada K
    Ann Surg Oncol; 2022 Feb; 29(2):1281-1293. PubMed ID: 34608555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel combined carbohydrate antigen 19-9 and lymphocyte-to-monocyte ratio score can predict early recurrence of resectable pancreatic ductal adenocarcinoma.
    Yugawa K; Maeda T; Nagata S; Sakai A; Taketani K; Yamaguchi S; Konishi K; Hashimoto K
    Surg Today; 2023 Oct; 53(10):1199-1208. PubMed ID: 36943449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative serum CA19-9 predicts postoperative pancreatic fistula in PDAC patients: retrospective analysis at a single institution.
    Sugita H; Okabe H; Ogawa D; Hirao H; Kuroda D; Taki K; Tomiyasu S; Hirota M
    BMC Surg; 2022 Oct; 22(1):367. PubMed ID: 36307795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma.
    Newhook TE; Vreeland TJ; Griffin JF; Tidwell RSS; Prakash LR; Koay EJ; Ludmir EB; Smaglo BG; Pant S; Overman M; Wolff RA; Ikoma N; Maxwell J; Kim MP; Lee JE; Katz MHG; Tzeng CD
    Ann Surg; 2023 Mar; 277(3):484-490. PubMed ID: 36649067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative serum CA125 levels predict the prognosis in hyperbilirubinemia patients with resectable pancreatic ductal adenocarcinoma.
    Chen T; Zhang MG; Xu HX; Wang WQ; Liu L; Yu XJ
    Medicine (Baltimore); 2015 May; 94(19):e751. PubMed ID: 25984661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of preoperative and postoperative CA 19-9 normalization in pancreatic adenocarcinoma treated with neoadjuvant therapy or surgery first.
    DiPeri TP; Newhook TE; Prakash LR; Ikoma N; Maxwell JE; Kim MP; Lee JE; Katz MHG; Tzeng CD
    J Surg Oncol; 2022 Nov; 126(6):1021-1027. PubMed ID: 35726394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
    Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
    Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of γ-glutamyltransferase-to-albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery.
    Li S; Xu H; Wu C; Wang W; Jin W; Gao H; Li H; Zhang S; Xu J; Zhang W; Xu S; Li T; Ni Q; Yu X; Liu L
    Cancer Med; 2019 Feb; 8(2):572-584. PubMed ID: 30632317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive Early Recurrence Factors of Preoperative Clinicophysiological Findings in Pancreatic Cancer.
    Suzuki S; Shimoda M; Shimazaki J; Maruyama T; Oshiro Y; Nishida K; Sahara Y; Nagakawa Y; Tsuchida A
    Eur Surg Res; 2018; 59(5-6):329-338. PubMed ID: 30453288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma.
    Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
    Scand J Gastroenterol; 2019 Jun; 54(6):780-786. PubMed ID: 31180790
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.